US2006239997A1PendingUtilityA1
Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
Est. expiryMar 31, 2015(expired)· nominal 20-yr term from priority
Inventors:Philip A. SwainVictoria C. SchadJulia L. GreensteinMark A. ExleyBarbara S. FoxStephen P. PowersMalcolm L. Gefter
A61P 39/00A61P 37/04A61P 25/30A61K 39/0013A61K 2039/6037A61P 25/34A61K 47/646C07K 16/44
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.
Claims
exact text as granted — not AI-modified88 . A hapten-carrier conjugate having the structure shown in FIG. 17B , wherein A, B, C, D, E, and F are side chains of nicotine, which are each independently selected from the chemical moieties identified by CJ reference number, consisting of:
CJ 0
Q
CJ 1
(CH 2 ) n Q
CJ 1.1
CO 2 Q
CJ 1.2
COQ
CJ 2
OCO(CH 2 ) n Q
CJ 2.1
OCOCH═Q
CJ 2.2
OCOCH(O)CH 2
CJ 2.3
OCO(CH 2 ) n CH 2
CJ 3
CO(CH 2 ) n COQ
CJ 3.1
CO(CH 2 ) n CNQ
CJ 4
OCO(CH 2 ) n COQ
CJ 4.1
OCO(CH 2 ) n CNQ
CJ 5
CH 2 OCO(CH 2 ) n COQ
CJ 5.1
CH 2 OCO(CH 2 ) n CNQ
CJ 6
CONH(CH 2 ) n Q
CJ 7
Y(CH 2 ) N q
CJ 7.1
CH 2 Y(CH 2 ) n Q
CJ 8
OCOCH(OH)CH 2 Q
CJ 8.1
OCO(CH 2 ) n CH(OH)CH 2 Q
CJ 9
OCOC 6 H 5
CJ 10
CJ10 shown on FIG. 2b
CJ 11
YCO(CH 2 )nCOQ;
wherein Y is sulfur (S), oxygen (O), or an amine (NH), and wherein n is an integer, and wherein Q is H, OH, OCH 3 , CH 2 , CH 3 , COOH, a halogen, an activated ester, a mixed anhydride, an acyl halide, an acyl azide, an alkyl halide, N-maleimide, an imino ester, isocyanate, isothiocyanate, or another branch identified by its CJ reference number, with the proviso that at least one A, B, C, D, E, or F further comprises a T-cell epitope-containing carrier.
89 . The hapten-carrier conjugate of claim 88 , wherein n is 2.
90 . The hapten-carrier conjugate of claim 88 , wherein n is an integer from 3 to 20.
91 . A hapten-carrier conjugate of the formula
wherein n is an integer, and the carrier is a T-cell epitope-containing carrier.
92 . The hapten-carrier conjugate of claim 91 , wherein n is 2.
93 . The hapten-carrier conjugate of claim 91 , wherein n is an integer from 3 to 20.
94 . The hapten-carrier conjugate of claim 88 , wherein the carrier is a protein, a peptide, a bacterial toxin, a product of a bacterial toxin, a subviral, lectin, an allergen, a fragment of an allergen, a malarial protein antigen, an artificial multi-antigenic peptide, or a modification, analog or a derivative thereof.
95 . The hapten-carrier conjugate of claim 88 , wherein the carrier is cholera toxin B, diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, Shiga toxin, pseudomonas exotoxin, ricin B subunit, abrin, sweet pea lectin, retrovirus nucleoprotein, rabies nucleoprotein, tobacco mosaic virus, cauliflower mosaic virus, vesicular stomatitis virus-nucleocapsid protein, poxvirus subunit, Semliki forest virus vector or yeast virus-like particle.
96 . The hapten-carrier conjugate of claim 91 , wherein the carrier is a protein, a peptide, a bacterial toxin, a product of a bacterial toxin, a subviral, lectin, an allergen, a fragment of an allergen, a malarial protein antigen, an artificial multi-antigenic peptide, or a modification, analog or a derivative thereof.
97 . The hapten-carrier conjugate of claim 91 , wherein the carrier is cholera toxin B, diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, Shiga toxin, pseudomonas exotoxin, ricin B subunit, abrin, sweet pea lectin, retrovirus nucleoprotein, rabies nucleoprotein, tobacco mosaic virus, cauliflower mosaic virus, vesicular stomatitis virus-nucleocapsid protein, poxvirus subunit, Semliki forest virus vector or yeast virus-like particle.
98 . The hapten-carrier conjugate of claim 95 , wherein the carrier is cholera toxin B (CTB).
99 . The hapten-carrier conjugate of claim 97 , wherein the carrier is cholera toxin B (CTB).
100 . A therapeutic composition comprising the hapten-carrier conjugate of claim 88 and a pharmaceutically acceptable carrier.
101 . A therapeutic composition comprising the hapten-carrier conjugate of claim 91 and a pharmaceutically acceptable carrier.
102 . A therapeutic composition comprising the hapten-carrier conjugate of claim 99 and a pharmaceutically acceptable carrier.
103 . The therapeutic composition of claim 100 further comprising an adjuvant.
104 . The therapeutic composition of claim 101 further comprising an adjuvant.
105 . The therapeutic composition of claim 102 further comprising an adjuvant.
106 . The therapeutic composition of claim 103 , wherein the adjuvant is alum, MF-59 or RIBI adjuvant.
107 . The therapeutic composition of claim 104 , wherein the adjuvant is alum, MF-59 or RIBI adjuvant.
108 . The therapeutic composition of claim 105 , wherein the alum is aluminum hydroxide or aluminum phosphate.
109 . The therapeutic composition of claim 100 , wherein the composition is suitable for oral, dermal, intranasal or parenteral administration.
110 . The therapeutic composition of claim 101 , wherein the composition is suitable for oral, dermal, intranasal or parenteral administration.
111 . The therapeutic composition of claim 102 , wherein the composition is suitable for oral, dermal, intranasal or parenteral administration.
112 . A method of inducing an immune response in a subject in need thereof, the method comprising administering the subject an effective amount of the composition of claim 100 .
113 . A method of inducing an immune response in a subject in need thereof, the method comprising administering the subject an effective amount of the composition of claim 101 .
114 . A method of inducing an immune response in a subject in need thereof, the method comprising administering the subject an effective amount of the composition of claim 102 .
115 . A method of preventing and/or treating nicotine addiction, the method comprising administering to a subject in need thereof an effective amount of the composition of claim 100 .
116 . A method of preventing and/or treating nicotine addiction, the method comprising administering to a subject in need thereof an effective amount of the composition of claim 101 .
117 . A method of preventing and/or treating nicotine addiction, the method comprising administering to a subject in need thereof an effective amount of the composition of claim 102 .
118 . The method of claim 112 , wherein the subject is a mammal.
119 . The method of claim 113 , wherein the subject is a mammal.
120 . The method of claim 114 , wherein the subject is a mammal.
121 . The method of claim 112 , wherein the subject is a human.
122 . The method of claim 113 , wherein the subject is a human.
123 . The method of claim 114 , wherein the subject is a human.
124 . The method of claim 115 , wherein the subject is a human.
125 . The method of claim 116 , wherein the subject is a human.
126 . The method of claim 117 , wherein the subject is a human.
127 . The method of claim 126 , wherein the composition is administered intranasally, intratracheally or parenterally.Join the waitlist — get patent alerts
Track US2006239997A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.